<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00981747</url>
  </required_header>
  <id_info>
    <org_study_id>200906736</org_study_id>
    <nct_id>NCT00981747</nct_id>
  </id_info>
  <brief_title>Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>A Clinical Treatment Trial Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pulmonary Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether combination therapy with sildenafil and
      losartan can improve function and exercise tolerance in patients with idiopathic pulmonary
      fibrosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2009</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Six minute walk test</measure>
    <time_frame>Every 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life Score</measure>
    <time_frame>Every 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>oxygenation (pO2)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biomarkers (Brain natriuretic peptide,angiotensin II, insulin-like growth factor, 8-isoprostane in exhaled breath condensate)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diffusing Capacity</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Borg dyspnea scale</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <condition>Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Sildenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sildenafil and Losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>Sildenafil 20mg three times per day for 3 months</description>
    <arm_group_label>Sildenafil</arm_group_label>
    <other_name>Viagra</other_name>
    <other_name>Revatio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Losartan 25mg two times a day for 3 months</description>
    <arm_group_label>Losartan</arm_group_label>
    <other_name>Cozaar: losartan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil and Losartan</intervention_name>
    <description>Sildenafil 20mg three times per day and Losartan 25mg two times per day.</description>
    <arm_group_label>Sildenafil and Losartan</arm_group_label>
    <other_name>Viagra, Revatio: sildenafil</other_name>
    <other_name>Cozaar: losartan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pill</intervention_name>
    <description>Placebo pill three times per day for 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo pill (sugar)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-99

          -  Have not taken any of the study medications in the past 6 weeks

          -  Diagnosed with idiopathic pulmonary fibrosis

        Exclusion Criteria:

          -  FVC&lt;50%, DLco &lt;30% or FEV1/FVC ratio &lt;65%

          -  Greater amount of emphysema than fibrotic change on chest CT scan

          -  Acute myocardial infarction within the past 6 months

          -  Nitrate use

          -  Contraindications, hypersensitivity, or allergic reaction to any study medication

          -  Presence of aortic stenosis

          -  Life-threatening arrhythmia within 1 month of evaluation

          -  Diabetes requiring insulin therapy

          -  Second-degree or third-degree atrioventricular block on electrocardiogram

          -  Echocardiographic evidence of severe pulmonary hypertension (&gt;50mmHg) â€¢ Severe
             terminal illness (survival predicted to be less than 1 year)

          -  Severe congestive heart failure

          -  Renal impairment (creatinine &gt;2.0 mg/dl)

          -  Moderate to severe hepatic impairment

          -  Concurrent treatment with immunosuppressive, cytotoxic, or investigational agents.

          -  Pregnant or Breastfeeding (Women of childbearing age must use effective form of birth
             control or abstinence during study participation)

          -  History of acute exacerbation of IPF

          -  Current enrollment in another investigational protocol

          -  Acute or chronic impairment other than dyspnea that limits the patient's ability to
             perform the six minute walk test

          -  Current drug or alcohol dependence

          -  Initiation of pulmonary rehabilitation within 30 days of enrollment. Subjects
             currently undergoing maintenance pulmonary rehabilitation at study entry will be asked
             to maintain their levels of rehabilitation for the duration of the trial

          -  Treatment of pulmonary hypertension with prostaglandins, endothelin-1 antagonists, or
             any other phosphodiesterase inhibitor within 30 days of enrollment

          -  Addition or discontinuation of calcium channel blockers, digitalis, diuretics or
             vasodilators within 30 days of enrollment. Dosage must be stable for 7 days prior to
             enrollment (except for diuretics)

          -  Listed for lung transplantation

          -  Due to drug interactions, all of the following agents will be prohibited:
             alpha-blockers, endothelin-1 antagonists, and CYP3A4 inhibitors

          -  Resting oxygen saturation of &lt;92% with greater than 6 liters of supplemental oxygen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alicia K Gerke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2009</study_first_submitted>
  <study_first_submitted_qc>September 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2009</study_first_posted>
  <last_update_submitted>March 29, 2017</last_update_submitted>
  <last_update_submitted_qc>March 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Alicia Gerke</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

